Table 2: Here
The mean score of VAS in the Silymarin group and placebo group were 5.77± 1.79 and 5.73± 1.98, respectively. The mean of final VAS was 2.13±1.45 in the silymarin group and 4.2±1.85 in the placebo group. Analysis of covariance showed that VAS in the intervention group decreased 1.99 times (95% CI: 1.001-2.975) more than the comparison group and this difference was statistically significant (p-value <0.0001) (Figure 2).